Sonus Pharmaceuticals/Abbott Labs
This article was originally published in The Gray Sheet
Executive Summary
Abbott will continue to manufacture Sonus' ultrasound contrast agent EchoGen until mid-2002, but will return to Sonus the marketing rights to the product for no cost under an agreement announced April 5. The companies are currently negotiating "appropriate amendments" to the existing manufacturing agreement